ArticleHaemophilia : the official journal of the World Federation of Hemophilia2018
Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.
Article in Haemophilia : the official journal of the World Federation of Hemophilia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).Journal of thrombosis and haemostasis : JTH · 2020Trial
- Time- and Temperature-Dependent Response of Acquired FV Inhibitors: Implications for Laboratory Diagnosis and Clinical Management.Journal of clinical laboratory analysis · 2026Article
- Laboratory Challenges in the Era of Novel Haemophilia Therapies.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Heat treatment of emicizumab samples - a way forward?Research and practice in thrombosis and haemostasis · 2026Article
- Turning up the heat: optimizing Bethesda assays for efanesoctocog alfa monitoring.Research and practice in thrombosis and haemostasis · 2025Article
- Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice.Nature communications · 2024Article
- Diagnosis and laboratory monitoring of acquired hemophilia A.Hematology. American Society of Hematology. Education Program · 2023Article
- A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review.Diagnostics (Basel, Switzerland) · 2022Article
- An Update on Laboratory Diagnostics in Haemophilia A and B.Hamostaseologie · 2022Review
- Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.Journal of blood medicine · 2022Review
- Acquired Haemophilia A: A Review of What We Know.Journal of blood medicine · 2022Review
- Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.Journal of thrombosis and haemostasis : JTH · 2021Article
- The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation.Blood transfusion = Trasfusione del sangue · 2020Article
- Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2020Article
- International recommendations on the diagnosis and treatment of acquired hemophilia A.Haematologica · 2020Article
- Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life haemophilia treatment products.Haemophilia : the official journal of the World Federation of Hemophilia · 2020Article
- Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.Haemophilia : the official journal of the World Federation of Hemophilia · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe use of pre-analytical heat treatment (PHT) with the Nijmegen-Bethesda assay (NBA) for inhibitors to factor VIII (FVIII) can remove/destroy infused or endogenous FVIII from patient plasma samples, allowing testing of recently infused patients with haemophilia. Two PHT methods have been described as follows: heating to 56°C for 30 minutes and heating to 58°C for 90 minutes. Data examining the effects of PHT on anti-FVIII IgG
aimTo assess the effect of PHT on the levels of detectable anti-FVIII IgG
methodsNijmegen-Bethesda assay-positive specimens were incubated at 56, 58 or 60°C for 90 minutes, and anti-FVIII IgG
resultsLevels of anti-FVIII IgG
conclusionThe optimal temperature for PHT in the FVIII NBA is 56°C. Higher temperatures may lead to loss of inhibitory antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.